Emergent BioSolutions Inc.'s shares surged over 16% in extended trading on Wednesday after advisory committees for the United States Food and Drug Administration recommended selling its nasal spray Narcan over the counter.
The spray is a "treatment of known or suspected opioid overdose, as...
Share prices of Emergent BioSolutions Inc. fell more than 40% on Friday, following the cancellation of its deal worth $628 million with the United States government to produce COVID-19 vaccines.
The company revealed details of the termination during its earnings call on Thursday, including that it...
The United States Food and Drug Administration (FDA) confirmed on Friday earlier reports about their decision regarding the Johnson & Johnson vaccines manufactured at the problematic Emergent BioSolutions plant.
According to the agency, two batches of the Johnson & Johnson vaccine have...
The United States Food and Drug Administration (FDA) is expected to release around 10 million Johnson & Johnson coronavirus vaccine jabs that were manufactured at the Emergent BioSolutions, which is under investigation for vaccine mishandling.
According to a report by the Washington Post on...
President and Chief Executive Officer of Emergent BioSolutions Robert Kramer stated on Wednesday that over 100 million Johnson and Johnson (J&J) COVID-19 vaccine doses are currently being held up by the Food and Drug Administration (FDA) while it investigates their safety after...
This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.
